AstraZeneca Acquires EsoBiotec in $425M Deal to Expand Cell Therapy Efforts

AstraZeneca has announced the acquisition of EsoBiotec, a biotechnology company specializing in allogeneic cell therapies, for $425 million. This move is part of AstraZeneca’s broader strategy to strengthen its position in the development of next-generation treatments for cancer and immune-mediated diseases. EsoBiotec’s technology focuses on in vivo reprogramming of patients’ immune cells, which aims to create off-the-shelf cell therapies that do not require patient-specific manufacturing.

The acquisition follows a series of similar deals by AstraZeneca as it seeks to expand its presence in the emerging field of cell therapy. Allogeneic cell therapies, such as those developed by EsoBiotec, are designed to be more accessible and scalable compared to autologous approaches that rely on harvesting and modifying a patient’s own cells. AstraZeneca’s investment underscores its commitment to advancing innovative treatment options for complex diseases while addressing challenges related to accessibility and production efficiency within the field.

Date: 18 March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

AstraZeneca Acquires Cell Therapy Company in $1 Billion Deal to Develop In Vivo Cancer Treatments Breakthrough in Skin Cancer Treatment: Promising Results from New Therapy Breakthrough in Cancer Vaccine Development Enhances Effectiveness and Reach Mechanisms Behind Oral Cancer Spread and Possible Treatment Approaches

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後